STOCK TITAN

Grace Therapeutics Q2 FY2027 loss widens to $2.13M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported a net loss of $2.131 million for the three months ended September 30, 2026, compared with $0.938 million a year earlier; loss per share was $0.11 versus $0.06. The company attributed the increase primarily to a $1.427 million favorable change in derivative warrant liabilities in the prior-year quarter that did not recur after the warrants expired, and higher research and development expenses, partly offset by lower general and administrative expenses.

Cash and cash equivalents were $21.311 million at September 30, 2026, and cash used in operations was approximately $5.0 million for the six months ended that date. An August 2026 private placement generated $9.2 million in net proceeds. The company believes its cash will support planned operations through the end of calendar 2028. For GTx-104, the CEO said the FDA’s Complete Response Letter identified no clinical safety or efficacy deficiencies; the company is addressing chemistry, manufacturing and controls and non-clinical items. Its dual-source manufacturing strategy is progressing, and NDA resubmission timing will reflect whichever site reaches readiness first.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointQuarterly net loss rose to $2.131 million from $0.938 million a year earlier.

Filing Explained

Grace reported 21,035,930 common shares issued and outstanding at September 30, 2026, versus 16,024,026 at March 31, 2026; for holders whose share counts did not change, the larger share base reduces their proportional ownership.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Net loss $2.131 million Three months ended September 30, 2026
Loss per share $0.11 Basic and diluted; three months ended September 30, 2026
Cash and cash equivalents $21.311 million As of September 30, 2026
Cash used in operations Approximately $5.0 million Six months ended September 30, 2026
Private placement net proceeds $9.2 million Completed in August 2026
Research and development expenses $0.885 million Three months ended September 30, 2026
General and administrative expenses $1.407 million Three months ended September 30, 2026
Complete Response Letter (CRL) regulatory
"items cited in the FDA’s CRL"
A complete response letter (CRL) is an official communication from a drug or medical device regulator saying an approval application cannot be approved in its current form and listing specific problems that must be fixed. For investors, a CRL is like a referee pausing a game and listing rule violations — it signals extra time, cost and uncertainty before a product can reach market, and it often prompts a reassessment of a company’s near-term prospects.
chemistry, manufacturing and controls (CMC) technical
"address the chemistry, manufacturing and controls (CMC)"
Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.
New Drug Application (NDA) regulatory
"resubmission of our New Drug Application (NDA)"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
derivative warrant liabilities financial
"fair value of derivative warrant liabilities"
Derivative warrant liabilities are the obligation a company records for outstanding warrants—contracts that give holders the right to receive cash or shares based on the company’s stock price. They matter to investors because these liabilities signal potential future cash outflows or share dilution that can reduce earnings per share, change available cash, and increase stock volatility; think of them as outstanding IOUs that may force a company to pay money or issue more shares.
aSAH medical
"aneurysmal Subarachnoid Hemorrhage (aSAH)"
Net loss $2.131 million Compared with $0.938 million in the three months ended September 30, 2025
Basic and diluted loss per share $0.11 Compared with $0.06 in the three months ended September 30, 2025
Research and development expenses $0.885 million Compared with $0.568 million in the three months ended September 30, 2025
General and administrative expenses $1.407 million Compared with $1.961 million in the three months ended September 30, 2025
Guidance

The company believes its existing cash and cash equivalents will be sufficient to sustain planned operations through the end of calendar 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was GRCE's net loss in the second quarter of fiscal 2027?

Grace Therapeutics reported a net loss of $2.131 million for the three months ended September 30, 2026, compared with $0.938 million for the three months ended September 30, 2025. Basic and diluted loss per share was $0.11, compared with $0.06.

How long does Grace Therapeutics expect its cash to last?

The company believes its existing cash and cash equivalents will be sufficient to sustain planned operations, including activities addressing the FDA's Complete Response Letter, through the end of calendar 2028. Cash and cash equivalents were $21.311 million as of September 30, 2026; cash used in operations was approximately $5.0 million for the six months ended that date.

What is Grace Therapeutics doing after the FDA's Complete Response Letter for GTx-104?

The company said it is addressing chemistry, manufacturing and controls and non-clinical data items. Its dual-source manufacturing strategy includes remediation at its current contract manufacturer and technology transfer to a second U.S.-based contract manufacturer. The company said NDA resubmission timing will reflect whichever manufacturing site reaches readiness first.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

graphic
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K
 


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2026

GRACE THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
 

State of Delaware
graphic
001-35776
98-1359336
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
103 Carnegie Center


Suite 300


Princeton, New Jersey
08540
(Address of Principal Executive Offices)
(Zip Code)

Registrant’s Telephone Number, Including Area Code: 609-322-1602

(Former Name or Former Address, if Changed Since Last Report)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class  
Trading
Symbol(s)
  Name of each exchange on which registered





Common Stock, par value $0.0001 per share
  GRCE
  The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


Item 2.02
Results of Operations and Financial Condition.
 
The following information is furnished pursuant to Item 2.02 “Results of Operations and Financial Condition.”
 
On November 12, 2026, Grace Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
 
The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing or document.
 
Item 9.01
Exhibits.
 
(d)
Exhibits
 
Exhibit
Description
99.1
Press Release, dated November 12, 2026.
104

Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 


GRACE THERAPEUTICS, INC.



Date: November 12, 2026
By: /s/ Prashant Kohli


Prashant Kohli


Chief Executive Officer




Exhibit 99.1


Grace Therapeutics Announces Second Quarter 2027 Financial Results,
Provides Business Update

Princeton, N.J., November 12, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended September 30, 2026.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104,” said Prashant Kohli, Chief Executive Officer of Grace Therapeutics. “Our dual-source manufacturing strategy to address potential remediation issues at our current contract manufacturer is progressing, and the timing of our NDA resubmission will reflect whichever manufacturing site reaches readiness first. The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission. We look forward to reporting our progress as we work toward achieving these important milestones.”

Second Quarter 2027 and Recent Corporate Highlights


•
Completed a $10 million private placement financing with certain institutional and accredited investors. The Company intends to use the net proceeds from the financing to support the manufacturing and regulatory work needed to advance GTx-104.


•
Announced receipt of the FDA meeting minutes from a Type A Meeting held with the FDA to discuss the CRL issued on April 23, 2026. The FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data. The Company is working on its previously disclosed plan to address the identified issues and will report progress as key milestones are achieved.


•
Initiated a dual-source manufacturing strategy for GTx-104 to address potential remediation issues from its current contract manufacturing organization (CMO). The Company’s current CMO has responded to the FDA, submitted a corrective action plan, and, the Company believes, is executing that plan in direct communication with the FDA. Reinspection timing depends on the current CMO’s readiness and FDA scheduling. In parallel, technology transfer was initiated during the quarter ended September 30, 2026 to a second, U.S.-based CMO, starting with analytical method transfer. The Company has also initiated the required non-clinical studies. The NDA resubmission may be supported by either CMO, or both, and its timing will reflect the pathway that reaches readiness first.
 
Second Quarter 2027 Financial Results
 
The Company reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026, an increase of $1.2 million from the net loss of $0.9 million, or $0.06 per share, for the three months ended September 30, 2025. The increase in net loss was primarily due to a $1.4 million favorable change in the fair value of derivative warrant liabilities recorded during the three months ended September 30, 2025 with no such activity recorded in the three months ended September 30, 2026 as the applicable warrants have expired, as well as an increase in research and development expenses of $0.3 million, offset partially by a $0.6 million decrease in general and administrative expenses.

Total research and development expenses for the three months ended September 30, 2026 were $0.9 million, compared to $0.6 million for the three months ended September 30, 2025. The increase of $0.3 million primarily reflected higher third-party research activities related to the dual-source manufacturing strategy for GTx-104 and the required non-clinical studies identified in the CRL.


General and administrative expenses were $1.4 million for the three months ended September 30, 2026, a decrease of $0.6 million from $2.0 million for the three months ended September 30, 2025. The decrease was primarily the result of a $0.3 million decrease in professional fees primarily related to decreased legal fees, a $0.1 million decrease in pre-commercial planning activities for GTx-104, and a $0.1 million decrease in salaries and benefits.

Cash Runway

As of September 30, 2026, cash and cash equivalents were $21.3 million, a net increase of $4.3 million compared to cash and cash equivalents of $17.0 million at March 31, 2026.  Cash used in operations for the six months ended September 30, 2026 was approximately $5.0 million.  As announced in August 2026, the Company completed a private placement of its common stock with certain institutional and accredited investors. Net proceeds to the Company were $9.2 million. The Company plans to use its existing cash and cash equivalents towards resolving the items cited in the FDA’s CRL, working capital and other general corporate purposes. The Company believes its existing cash and cash equivalents will be sufficient to sustain planned operations, including the activities to address the items cited in the CRL, through the end of calendar 2028.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients per year.

About GTx-104

GTx-104 is a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.


For more information, please visit: www.gracetx.com.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including, but not limited to, statements regarding the Company’s cash runway and its planned uses of its existing cash and cash equivalents; the Company’s intended uses of the net proceeds from the August 2026 financing; future prospects of GTx-104; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of the NDA for GTx-104; the Company’s planned approach to addressing the items cited in the CRL; the Company’s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company’s belief that its current contract manufacturer is executing the corrective action plan in direct communication with the FDA; the Company’s plans to complete the required non-clinical studies; the Company’s plans to report progress against key milestones; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the timing and success of any regulatory resubmission of the NDA for GTx-104; (ii) the ability of the Company’s current contract manufacturer to regain compliance and generate the required leachables data, the timing of any FDA reinspection of that contract manufacturer, and that facility’s compliance status, which are determined by the FDA and outside the Company’s control, and the FDA’s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iii) the ability of a second, U.S.-based contract manufacturer to complete the technology transfer, manufacture three registration batches, generate the required 12 months of stability data, analytical data and leachables data, and complete a product-specific pre-approval inspection; (iv) the need to complete additional non-clinical studies; (v) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vi) the Company’s potential need for additional capital, which may not be available on acceptable terms; (vii) changes to regulatory pathways; (viii) the Company’s ability to protect its intellectual property for GTx-104; and (ix) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026, the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (SEC) and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.

For more information, please contact:

Grace Therapeutics Contact:
 
Prashant Kohli
 
Chief Executive Officer
 
Tel: 609-322-1602
 
Email: info@gracetx.com
 
www.gracetx.com
 
Investor Relations:
 
LifeSci Advisors
 
Mike Moyer
 
Managing Director
 
Phone: 617-308-4306
 
Email: mmoyer@lifesciadvisors.com
 

---tables to follow---


GRACE THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(Unaudited)
   
September 30, 2026
   
March 31, 2026
 
(Expressed in thousands except share data)
 
$
   
$
 
Assets
               
Current assets:
               
Cash and cash equivalents
   
21,311
     
16,977
 
Receivables
   
20
     
20
 
Prepaid expenses
   
629
     
383
 
Total current assets
   
21,960
     
17,380
 
Equipment, net
   
5
     
8
 
Intangible assets
   
27,595
     
41,128
 
Goodwill
   
8,138
     
8,138
 
Total assets
   
57,698
     
66,654
 
                 
Liabilities and Stockholders’ equity
               
Current liabilities:
               
Trade and other payables
   
1,614
     
2,146
 
Total current liabilities
   
1,614
     
2,146
 
                 
Deferred tax liability
   
604
     
612
 
Total liabilities
   
2,218
     
2,758
 
                 
Commitments and contingencies
               
                 
Stockholders’ equity:
               
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of September 30, 2026 and March 31, 2026
   
—
     
—
 
Common stock, $0.0001 par value per share; 100,000,000 authorized; 21,035,930 and 16,024,026 shares issued and outstanding as of September 30, 2026 and March 31, 2026, respectively
   
2
     
1
 
Additional paid-in capital
   
307,917
     
298,413
 
Accumulated other comprehensive loss
   
(6,038
)
   
(6,038
)
Accumulated deficit
   
(246,401
)
   
(228,480
)
Total stockholders’ equity
   
55,480
     
63,896
 
Total liabilities and stockholders’ equity
   
57,698
     
66,654
 


GRACE THERAPEUTICS, INC.
Condensed Consolidated Statements of Loss and Comprehensive Loss
(Unaudited)

   
Three months ended
   
Six months ended
 
   
September 30,
2026
   
September 30,
2025
   
September 30,
2026
   
September 30,
2025
 
(Expressed in thousands, except share and per share data)
                       
   
$
   
$
   
$
   
$
 
                                 
Operating expenses
                               
Research and development expenses
   
(885
)
   
(568
)
   
(1,582
)
   
(1,523
)
General and administrative expenses
   
(1,407
)
   
(1,961
)
   
(3,094
)
   
(4,096
)
Impairment of intangible assets
   
—
     
—
     
(13,533
)
   
—
 
Loss from operating activities
   
(2,292
)
   
(2,529
)
   
(18,209
)
   
(5,619
)
                                 
Foreign exchange (loss) gain
   
(1
)
   
(8
)
   
(15
)
   
3
 
Change in fair value of derivative warrant liabilities
   
—
     
1,427
     
—
     
940
 
Interest and other income, net
   
154
     
172
     
295
     
375
 
Total other income, net
   
153
     
1,591
     
280
     
1,318
 
Loss before income tax benefit
   
(2,139
)
   
(938
)
   
(17,929
)
   
(4,301
)
                                 
Income tax benefit
   
8
     
—
     
8
     
—
 
                                 
Net loss and total comprehensive loss
   
(2,131
)
   
(938
)
   
(17,921
)
   
(4,301
)
                                 
Basic and diluted loss per share
 

($0.11
)
 

($0.06
)
 

($0.96
)
 

($0.27
)
                                 
Weighted-average number of shares outstanding
   
20,116,776
     
15,924,522
     
18,701,159
     
15,924,522
 



Filing Exhibits & Attachments

4 documents

Keep reading